 Systemic lupus erythematosus, SLE, is a severe autoimmune disease that affects multiple systems and threatens human life. B cells play a pivotal role in the pathogenesis of SLE, with abnormal expression and activation leading to inflammation and tissue damage. New therapies targeting B cells are needed, and Illinois, 21 and plasma cell depletion drugs may provide potential therapeutic targets and strategies for SLE. This article was authored by Yu Feng, Ming Yang, Hai Jing Wu, and others.